Division of Pediatric Surgery, Department of Surgery, Fetal Treatment Center, University of California, San Francisco, 513 Parnassus Avenue, HSW 16-01, Box 0570, San Francisco, CA 94143-0570, USA.
Clin Perinatol. 2012 Jun;39(2):279-88. doi: 10.1016/j.clp.2012.04.003. Epub 2012 May 15.
Myelomeningocele (MMC) is a congenital neural tube defect that occurs in approximately 1 in 2900 live births in the United States. It is a devastating disability with significant morbidity and mortality within the first few decades of life. MMC was the first nonlethal disease to be considered and studied for fetal surgery and is now the most common open fetal surgery performed. The recently completed MOMS randomized controlled trial has shown that fetal repair for MMC can improve hydrocephalus and hindbrain herniation, can reduce the need for vetriculoperitoneal shunting, and may improve distal neurologic function in some patients.
脊髓脊膜膨出(MMC)是一种先天性神经管缺陷,在美国,大约每 2900 例活产中就会发生一例。这是一种毁灭性的残疾,在生命的头几十年内有很高的发病率和死亡率。MMC 是第一个被考虑并研究胎儿手术的非致死性疾病,现在是最常见的开放性胎儿手术。最近完成的 MOMS 随机对照试验表明,MMC 的胎儿修复可以改善脑积水和后脑疝,减少脑室-腹腔分流的需求,并可能改善某些患者的远端神经功能。